Lantern Pharma, Inc. (LTRN)
|Net Income (ttm)||n/a|
|Trading Day||January 15|
|Day's Range||13.77 - 14.75|
|52-Week Range||10.70 - 21.25|
DALLAS, Jan. 14, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cance...
Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma
DALLAS and LA JOLLA, Calif., Jan. 4, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platfor...
Lantern Pharma, a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent... [Read more...]
|IPO Date |
Jun 11, 2020
|Stock Exchange |
|Ticker Symbol |
According to 2 analysts, the average rating for Lantern Pharma stock is "Buy." The 12-month stock price forecast is 27.33, which is an increase of 90.59% from the latest price.